Schedule of Noncontrolling Interest of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Noncontrolling Interest [Abstract]
NCI – equity - December 31, 2023			$ 29,813
Net loss attributable to NCI	$ (3,688)	$ (4,079)	(11,075)	$ (11,716)
Impact of subsidiary equity transactions			(4,414)
Lucid Diagnostics proceeds from issuance of preferred stock Series A-1			5,670
Lucid Diagnostics exchange of preferred stock Series A and Series A-1			(24,294)
Lucid Diagnostics issuance through exchange - Series B and Series B-1			31,790
Lucid Diagnostics issuance through sale - Series B and Series B-1			24,129
Lucid Diagnostics deemed dividend on preferred stock			(7,496)
Lucid Diagnostics issuance of common stock for settlement of vendor service agreement			401
Lucid Diagnostics 2018 Equity Plan stock option exercise			4
Lucid Diagnostics Employee Stock Purchase Plan Purchase			353
Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt			3,801
Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan			2,771
Stock-based compensation expense - Veris Health 2021 Equity Plan			368
Deconsolidation of Lucid			(56,339)
NCI – equity - September 30, 2024	$ (4,518)		$ (4,518)